Therapeutics News

Aclaris Therapeutics announced positive results from a phase 3 clinical trial of A-101 45% topical solution, an investigational new drug for the treatment of common warts.

Alopecia areata affects up to 6.8 million people in the U.S. and carries a 2.1% lifetime risk, according to the National Alopecia Areata Foundation. The foundation has dubbed September “Alopecia Areata Awareness Month” to increase awareness, spread empowerment and raise funds for research into this polygenic autoimmune disease.

Methotrexate may be used as a third-line therapy for treating chronic spontaneous urticaria, but it was not superior to placebo added to H1-antihistamines, according to a research letter in the Journal of the American Academy of Dermatology.

Earlier this month, Healio Dermatology posted a compilation of eight popular reads to kickoff Psoriasis Action Month in psoriasis research, advocacy and FDA news.

Based on the available literature, the American Academy of Dermatology and the National Psoriasis Foundation published joint guidelines on ultraviolet light-based therapies for the treatment of psoriasis.

Bausch Health announced the expansion of its dermatology prescription program with Walgreens stores in the U.S.

Biologic therapy for moderate to severe psoriasis reduced in coronary inflammation, as assessed by perivascular fat attenuation index via coronary CTA, a measurement that may be able to track response to CAD interventions, researchers reported in JAMA Cardiology.

The use of cyclosporine, infliximab and anti-IL17 in the treatment of psoriasis is associated with a higher risk for symptomatic urinary tract infection in women, according to a 10-year observational study.

NEW YORK — Systemically administered Janus kinase inhibitors hold potential for the treatment of alopecia areata and vitiligo, a presenter said here.

Cara Therapeutics announced the commencement of a phase 2 trial for oral Korsuva for the treatment of pruritus in patients with atopic dermatitis.